Table 1 Summary of current clinical trial PFS data on which statistical calculations are based

BOND study [1] cetuximab alone vs cetuximab + irinotecan

6 m PFS = 8 % vs. 30 %

NA

NA

NA

CO.17 [4] cetuximab vs best supportive care

N/A

6 m PFS cetuximab = 30 %

6 m PFS < 5 %

De Roock [11] cetuximab vs no cetuximab

N/A

Median PFS 4.2 m vs 1.9 m

Median PFS 1.9 m vs 1.8 m

Median PFS 4.0 m vs 1.7 m

Tepjar [12] cetuximab vs no cetuximab as 1st line treatment

Not relevant

Median PFS 9.6 m vs 7.6 m

Median PFS 6.7 m vs 8.1 m

Median PFS 7.4 m vs 6.0 m